Skip to main content

Table 1 Baseline characteristics of BV users

From: Effect of Broncho-Vaxom (OM-85) on the frequency of chronic obstructive pulmonary disease (COPD) exacerbations

Variables

Numbers (n = 238)

Age

69.2 ± 9.14

Sex (male)

190 (79.8%)

Insurance type

 Health insurance

207 (87.0%)

 Medical aid

31 (13.0%)

Hospital type

 Tertiary and general hospital

196 (82.4%)

 Others

42 (17.6%)

History of COPD AE

 None

131 (55.0%)

 1 moderate

85 (35.7%)

 ≥ 2 moderate or  ≥ 1 severe

22 (9.2%)

History of pneumonia

63 (26.5%)

mCCI

2.62 ± 2.12

COPD medication

 LAMA

24 (10.1%)

 LABA + LAMA

34 (14.3%)

 ICS + LABA

113 (47.5%)

 Triple

67 (28.2%)

  1. Data are presented as n (%) or mean ± SD
  2. BV Broncho-Vaxom, COPD Chronic obstructive pulmonary disease, AE Acute exacerbation, mCCI Modified Carlson Comorbidity Index, LAMA Long-acting muscarinic antagonist, LABA Long-acting beta2-agonist, ICS Inhaled corticosteroids